A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Carcinoma, Non-Small-Cell Lung|Carcinoma, Renal Cell|Breast Neoplasms|Urinary Bladder Neoplasm|Carcinoma, Squamous Cell of Head and Neck|Colorectal Neoplasms|Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma
Interventions: DRUG: SGN-2FF|DRUG: pembrolizumab
Sponsor: Seagen Inc.